Panel talk about Inify’s fourth quarter 2024
Inify Laboratories continues to strengthen its position in the diagnostics market, achieving significant growth and expanding its reach. In Q4 2024, sales increased by 60% compared to the previous quarter and 472% compared to Q4 2023. By the end of the year, Inify held around 80% of the prostate diagnostics market in the Stockholm region and signed its first agreement with a regional healthcare provider—marking an important milestone for its domestic expansion. Full-year sales reached SEK 13.7 million, compared to SEK 1.2 million the previous year.
Building on this success, Inify is making strong progress in its expansion into the UK healthcare market. The company is strengthening its presence through strategic recruitment and ongoing assessments of potential locations. With plans to establish a UK laboratory in 2025, Inify aims to begin clinical operations in early 2026, reinforcing its commitment to both NHS and private healthcare providers.
In addition to its geographical expansion, Inify is broadening its diagnostic services to include the gastrointestinal field. The company is preparing its laboratory to handle these samples and is working closely with clinicians to ensure its diagnostic services optimally support the patient pathway, using the same proven approach as in its prostate diagnostics.
Join Ole Eikeland and CEO Fredrik Palm for an insightful panel discussion on the UK diagnostics market, where they’ll explore key similarities and differences between the Swedish and UK markets. Learn about the factors behind Inify’s exceptional growth and hear about an exciting development planned for the second half of 2025.
Link to the panel talk is avialiable here.
For more information, contact CEO Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com.
Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.
